Ask
Search
My library

About
Statistics
Contact
Data Protection
Accessibility
Imprint
Changelog
Frontend: v1.31.3
Backend: v1.11.4

We use cookies to provide a better user experience.

Data Protection

EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis

Heyn, Holger
Esteller, Manel

Publication date

May 2013

DOI

10.1016/j.ccr.2013.04.028

Publisher

Elsevier Inc.

ISSN

1535-6108

Citation count (estimate)

9

Abstract

In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B cell activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible process is specifically targetable and hence presents high translational value for lymphoma therapy

Extracted data

Related items

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas

Yamagishi Makoto
Hori Makoto
Fujikawa Dai
Ohsugi Takeo
Honma Daisuke
Adachi Nobuaki
Katano Harutaka
Hishima Tsunekazu
Kobayashi Seiichiro
Nakano Kazumi
Nakashima Makoto
Iwanaga Masako
Utsunomiya Atae
Tanaka Yuetsu
Okada Seiji
Tsukasaki Kunihiro
Tobinai Kensei
Araki Kazushi
Watanabe Toshiki
Uchimaru Kaoru

November 2019

Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy fo...

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

Su, I-hsin
Talukder, Asoke K.
Nojima, Takuya
Doglioni, Claudio
Kitamura, Daisuke
Toellner, Kai-M
Casola, Stefano
Caganova, Marieta
Carrisi, Chiara
Varano, Gabriele
Mainoldi, Federica
Zanardi, Federica
Germain, Pierre-Luc
George, Laura
Alberghini, Federica
Ferrarini, Luca
Ponzoni, Maurilio
Testa, Giuseppe

January 2013

Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, ...

EZH2: novel therapeutic target for human cancer

李龍緣

[[abstract]]Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycom...

Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2

Melnick, Ari

November 2012

The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in ...

EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis

Heyn, Holger
Esteller, Manel

May 2013

In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B...

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

May 2013

SummaryThe EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and ta...

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty-Rao, Shivani
Nasveschuk, Christopher
Gagnon, Alexandre
Chan, Eric Y.
Sandy, Peter
Busby, Jennifer
Balasubramanian, Srividya
Campbell, Robert
Zhao, Feng
Bergeron, Louise
Audia, James E.
Albrecht, Brian K.
Harmange, Jean-Christophe
Cummings, Richard
Trojer, Patrick

November 2013

SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...

Targeting Epigenetic Regulators for the Treatment of Diffuse Large B-Cell Lymphoma

Goverdhan, Aarthi

August 2017

Small-molecule inhibitors of the histone methyltransferase EZH2 hold great promise for the treatment...

Targeting Epigenetic Regulators for the Treatment of Diffuse Large B-Cell Lymphoma

Goverdhan, Aarthi

August 2017

Small-molecule inhibitors of the histone methyltransferase EZH2 hold great promise for the treatment...

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

January 2016

As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcri...

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

May 2013

SummaryThe EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and ta...

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

de Vries, Nienke A.
Hulsman, Danielle
Akhtar, Waseem
de Jong, Johann
Miles, Denise C.
Blom, Marleen
van Tellingen, Olaf
Jonkers, Jos
van Lohuizen, Maarten

January 2015

SummaryEZH2 is frequently overexpressed in glioblastoma (GBM), suggesting an oncogenic function that...

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Bradley, William D.
Arora, Shilpi
Busby, Jennifer
Balasubramanian, Srividya
Gehling, Victor S.
Nasveschuk, Christopher G.
Vaswani, Rishi G.
Yuan, Chih-Chi
Hatton, Charlie
Zhao, Feng
Williamson, Kaylyn E.
Iyer, Priyadarshini
Méndez, Jacqui
Campbell, Robert
Cantone, Nico
Garapaty-Rao, Shivani
Audia, James E.
Cook, Andrew S.
Dakin, Les A.
Albrecht, Brian K.
Harmange, Jean-Christophe
Daniels, Danette L.
Cummings, Richard T.
Bryant, Barbara M.
Normant, Emmanuel
Trojer, Patrick

November 2014

SummaryThe histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an...

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty-Rao, Shivani
Nasveschuk, Christopher
Gagnon, Alexandre
Chan, Eric Y.
Sandy, Peter
Busby, Jennifer
Balasubramanian, Srividya
Campbell, Robert
Zhao, Feng
Bergeron, Louise
Audia, James E.
Albrecht, Brian K.
Harmange, Jean-Christophe
Cummings, Richard
Trojer, Patrick

November 2013

SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...

EZH2: novel therapeutic target for human cancer

李龍緣

[[abstract]]Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycom...

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas

Yamagishi Makoto
Hori Makoto
Fujikawa Dai
Ohsugi Takeo
Honma Daisuke
Adachi Nobuaki
Katano Harutaka
Hishima Tsunekazu
Kobayashi Seiichiro
Nakano Kazumi
Nakashima Makoto
Iwanaga Masako
Utsunomiya Atae
Tanaka Yuetsu
Okada Seiji
Tsukasaki Kunihiro
Tobinai Kensei
Araki Kazushi
Watanabe Toshiki
Uchimaru Kaoru

November 2019

Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy fo...

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

Su, I-hsin
Talukder, Asoke K.
Nojima, Takuya
Doglioni, Claudio
Kitamura, Daisuke
Toellner, Kai-M
Casola, Stefano
Caganova, Marieta
Carrisi, Chiara
Varano, Gabriele
Mainoldi, Federica
Zanardi, Federica
Germain, Pierre-Luc
George, Laura
Alberghini, Federica
Ferrarini, Luca
Ponzoni, Maurilio
Testa, Giuseppe

January 2013

Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, ...

EZH2: novel therapeutic target for human cancer

李龍緣

[[abstract]]Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycom...

Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2

Melnick, Ari

November 2012

The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in ...

EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis

Heyn, Holger
Esteller, Manel

May 2013

In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B...

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

May 2013

SummaryThe EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and ta...

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty-Rao, Shivani
Nasveschuk, Christopher
Gagnon, Alexandre
Chan, Eric Y.
Sandy, Peter
Busby, Jennifer
Balasubramanian, Srividya
Campbell, Robert
Zhao, Feng
Bergeron, Louise
Audia, James E.
Albrecht, Brian K.
Harmange, Jean-Christophe
Cummings, Richard
Trojer, Patrick

November 2013

SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...

Targeting Epigenetic Regulators for the Treatment of Diffuse Large B-Cell Lymphoma

Goverdhan, Aarthi

August 2017

Small-molecule inhibitors of the histone methyltransferase EZH2 hold great promise for the treatment...

Targeting Epigenetic Regulators for the Treatment of Diffuse Large B-Cell Lymphoma

Goverdhan, Aarthi

August 2017

Small-molecule inhibitors of the histone methyltransferase EZH2 hold great promise for the treatment...

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

January 2016

As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcri...

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

May 2013

SummaryThe EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and ta...

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

de Vries, Nienke A.
Hulsman, Danielle
Akhtar, Waseem
de Jong, Johann
Miles, Denise C.
Blom, Marleen
van Tellingen, Olaf
Jonkers, Jos
van Lohuizen, Maarten

January 2015

SummaryEZH2 is frequently overexpressed in glioblastoma (GBM), suggesting an oncogenic function that...

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Bradley, William D.
Arora, Shilpi
Busby, Jennifer
Balasubramanian, Srividya
Gehling, Victor S.
Nasveschuk, Christopher G.
Vaswani, Rishi G.
Yuan, Chih-Chi
Hatton, Charlie
Zhao, Feng
Williamson, Kaylyn E.
Iyer, Priyadarshini
Méndez, Jacqui
Campbell, Robert
Cantone, Nico
Garapaty-Rao, Shivani
Audia, James E.
Cook, Andrew S.
Dakin, Les A.
Albrecht, Brian K.
Harmange, Jean-Christophe
Daniels, Danette L.
Cummings, Richard T.
Bryant, Barbara M.
Normant, Emmanuel
Trojer, Patrick

November 2014

SummaryThe histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an...

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Garapaty-Rao, Shivani
Nasveschuk, Christopher
Gagnon, Alexandre
Chan, Eric Y.
Sandy, Peter
Busby, Jennifer
Balasubramanian, Srividya
Campbell, Robert
Zhao, Feng
Bergeron, Louise
Audia, James E.
Albrecht, Brian K.
Harmange, Jean-Christophe
Cummings, Richard
Trojer, Patrick

November 2013

SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...

EZH2: novel therapeutic target for human cancer

李龍緣

[[abstract]]Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycom...

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas

Yamagishi Makoto
Hori Makoto
Fujikawa Dai
Ohsugi Takeo
Honma Daisuke
Adachi Nobuaki
Katano Harutaka
Hishima Tsunekazu
Kobayashi Seiichiro
Nakano Kazumi
Nakashima Makoto
Iwanaga Masako
Utsunomiya Atae
Tanaka Yuetsu
Okada Seiji
Tsukasaki Kunihiro
Tobinai Kensei
Araki Kazushi
Watanabe Toshiki
Uchimaru Kaoru

November 2019

Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy fo...

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

Su, I-hsin
Talukder, Asoke K.
Nojima, Takuya
Doglioni, Claudio
Kitamura, Daisuke
Toellner, Kai-M
Casola, Stefano
Caganova, Marieta
Carrisi, Chiara
Varano, Gabriele
Mainoldi, Federica
Zanardi, Federica
Germain, Pierre-Luc
George, Laura
Alberghini, Federica
Ferrarini, Luca
Ponzoni, Maurilio
Testa, Giuseppe

January 2013

Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, ...

EZH2: novel therapeutic target for human cancer

李龍緣

[[abstract]]Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycom...